WAT

Waters Corporation (WAT) - Q2 2008 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 28, 2008. Waters Corporation designs, manufactures, and services analytical instrument systems, including liquid chromatography (LC), mass spectrometry (MS), and thermal analysis instruments. The company operates through two primary divisions: the Waters Division and the TA Division. The company is a large accelerated filer with 98,984,944 shares of common stock outstanding as of July 25, 2008.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 13% year-over-year for both the quarter and the six-month period. Growth was driven by demand in Asia (including Japan), expansion in industrial businesses, and favorable foreign currency translation (benefiting sales by 6%).
• Profitability: Net income per diluted share grew 39% for the quarter and 32% for the six-month period compared to the prior year.
• Accounting Adjustments: The company identified and corrected out-of-period errors in the second quarter. These errors involved an overstatement of income tax expense ($16.3 million) and an understatement of amortization expense ($8.7 million) related to capitalized software. The correction resulted in a net income increase of $7.6 million for the quarter and reduced the effective tax rate by 18.1 percentage points.
• Debt Structure: In March 2008, the company entered a new $150 million term loan facility. Total debt increased to $950 million under credit agreements, with $300 million classified as short-term due to the intent to repay within 12 months.

Guidance, Outlook, and Risks

• Outlook: Management expects selling and administrative expenses to grow at a slightly lower rate for the remainder of 2008. Inventory levels are expected to decrease in the second half of the year as sales of new products ramp up.
• Capital Allocation: The company repurchased $152.4 million of common stock during the six-month period. Approximately $181.5 million remains authorized for future repurchases under the 2007 program.
• Risks: Key risks include reliance on pharmaceutical and biotechnology customers (approx. 52% of sales), foreign currency fluctuations (70% of sales outside the U.S.), and potential disruptions in global manufacturing facilities. The company also faces risks related to intellectual property protection and shifts in taxable income between jurisdictions.
• Liquidity: Management believes cash balances ($830.7 million) and borrowing capacity ($298.5 million available) are sufficient to fund operations, capital spending, and share repurchases for the next 12 months.

Investor Verification Checklist

• Accounting Error Impact: Verify the long-term implications of the $16.3 million tax error correction and the $8.7 million amortization adjustment on future effective tax rates and expense recognition.
• Inventory Build-up: Monitor the $33.7 million increase in inventory over the six-month period to ensure it aligns with management's expectation of a drawdown in the second half of the year.
• Debt Maturity: Confirm the company's ability to service the $334 million in short-term debt obligations due within the next 12 months.
• Currency Exposure: Assess the sensitivity of future earnings to foreign exchange rates, given that 70% of sales are denominated in foreign currencies.
• Pharma Dependence: Evaluate the stability of the pharmaceutical and biotechnology sector, which accounts for over half of the company's revenue.